ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "medication"

  • Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium

    Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative

    Dori Abel1, Joyce Chang2, Jon Burnham3, Chen Kenyon4 and Sabrina Gmuca5, 1Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, 2Boston Children's Hospital, Boston, MA, 3Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
  • Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium

    The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

    Mary Beth Son1, Yukiko Kimura 2, Kristiina Aalto 3, Lillemor Berntson 4, Johnathan Dallas 1, Ciaran Duffy 5, Mia Glerup 6, Jaime Guzman 7, Troels Herlin 8, Petteri Hovi 9, Kimme Hyrich 10, Jens Klotsche 11, Bo Magnusson 12, Vanessa McIntyre 13, Ellen Nordal 14, Seza Ozen 15, Maria Jose Santos 16, Betul Sozeri 17 and Timothy Beukelman 18, 1Boston Children's Hospital, Boston, Massachusetts, 2Hackensack Meridian School of Medicine, Hackensack, 3Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 4Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 5Ottawa, Canada, 6Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 7University of British Columbia and BC Children's Hospital, Vancouver, Canada, 8Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, 9Helsinki University Hospital, Helsinki, Finland, 10Manchester, United Kingdom, 11Berlin, Germany, 12Karolinska University Hospital, Stockholm, Sweden, 13Manchester University, Manchester UK, United Kingdom, 14Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 15Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, 16Portugal, 17Boston, Turkey, 18University of Alabama at Birmingham, Birmingham

    Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
  • Abstract Number: 096 • 2020 Pediatric Rheumatology Symposium

    Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE

    Rotem Semo Oz1, Linda Wagner-Weiner 2, Cuoghi Edens 1, Grace Cameron 1 and Melissa Tesher 1, 1university of chicago, Chicago, 2University of Chicago, Chicago, Illinois

    Background/Purpose: Compared to adults with SLE, young patients with SLE face particular challenges, including more severe disease, more renal involvement and medications side effects like…
  • Abstract Number: 127 • 2020 Pediatric Rheumatology Symposium

    Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus

    Emily Smitherman1, Rouba Chahine 1, Timothy Beukelman 1, Laura Lewandowski 2, AKM Fazlur Rahman 1, Scott Wenderfer 3, Aimee Hersh 4 and Jeffrey R Curtis 5 for the CARRA investigators, 1University of Alabama at Birmingham, Birmingham, 2NIAMS, NIH, Rockville, 3Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 4University of Utah Primary Children's Hospital, Salt Lake City, 5University of Alabama at Birmingham, Hoover

    Background/Purpose: Lupus nephritis associated with childhood-onset systemic lupus erythematosus (cSLE) is a significant risk factor for long-term morbidity and mortality, but little is known regarding…
  • Abstract Number: 271 • 2019 ACR/ARP Annual Meeting

    Who Prescribed Which Osteoporosis Medication to Whom

    Jiannong Liu1, Haifebg Guo 1, Tingting Gong 1 and Yi Peng 2, 1Hennepin Healthcare Research Institute, Minneapolis, MN, 2Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN

    Background/Purpose: Several osteoporosis (OP) medicines came on the market in the past two decades, each with its own indications. However, there is no clear information…
  • Abstract Number: 2202 • 2019 ACR/ARP Annual Meeting

    Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014

    Jacek Kopec1, Jolanda Cibere 2, Na Lu 3, Hui Xie 4, J. Antonio Avina-Zubieta 1 and John Esdaile 5, 1Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, 5Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada

    Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly prescribed for patients with osteoarthritis (OA). However, both types of medication are associated with serious side…
  • Abstract Number: 2203 • 2019 ACR/ARP Annual Meeting

    Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study

    Jacek Kopec1, Eric Sayre 2, Anya Okhmatovskaia 3, Jolanda Cibere 4, Linda Li 5, Nick Bansback 6, Hubert Wong 5 and John Esdaile 7, 1Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, 2Arthritis Research Canada, Vancouver, BC, Canada, 3McGill University, Montreal, QC, Canada, 4Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, 5University of British Columbia, Vancouver, BC, Canada, 6University of British Columbia, Vancouver, Canada, 7Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada

    Background/Purpose: Analgesics are the cornerstone of medical treatment of osteoarthritis (OA) but are associated with serious side effects. A more optimal use of analgesics in…
  • Abstract Number: 2764 • 2019 ACR/ARP Annual Meeting

    Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis

    George Karpouzas1, Elizabeth Hernandez 2, Lorena Ruiz 3, Vibeke Strand 4 and Sarah Ormseth 1, 1Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, 2Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, 3Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, 4Division of Immunology/Rheumatology, Stanford University, Stanford, CA

    Background/Purpose: Medication adherence is instrumental for the successful management of rheumatoid arthritis (RA) to a goal of remission. Awareness of medication necessity and concerns regarding…
  • Abstract Number: 460 • 2018 ACR/ARHP Annual Meeting

    Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus

    Alaina M. Davis1, Marisa S. Klein-Gitelman2, Jennifer Faerber3, Hannah Katcoff4, Zuleyha Cidav5, David Mandell6 and Andrea M. Knight7, 1Division of Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, TN, 2Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 3Division of General Pediatrics, Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, 4Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, 5Perelman School of Medicine, Center for Mental Health Policy and Services Research, University of Pennsylvania, Philadelphia, PA, 6Psychiatry and Pediatrics, Center for Mental Health Policy and Services Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 7Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: To examine immunomodulatory medication use for youth with systemic lupus erythematosus (SLE) during their first year of care. Methods: We conducted a retrospective cohort…
  • Abstract Number: 1263 • 2018 ACR/ARHP Annual Meeting

    Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)

    Yan Zhao1, Jing Yang2, Jianlin Huang3, Hua Wei4, Yongfu Wang5, Rong Mu6, Xiaoxia Zuo7, Hongzhi Wang8, Xinwang Duan9, Jing Xue10, Hongsheng Sun11, Bin Wu12, Lirong Kang5, Feng Wei13, Cundong Mi14, Yanping Zhao15, Yang Li16, Haiying Chen17, Zhenbin Li18, Qingliang Meng19, Yuhua Jia20, Hui Xiao20 and Fei Xiao20, 1Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, 3Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, 4Northern Jiangsu People's Hospital, Yangzhou, China, 5The First Affiliated Hospital of BaoTou Medical College, Baotou, China, 6Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 7Xiangya Hospital Central South University, Changsha, China, 8The First Hospital of Jiaxing, Jiaxing, China, 9Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, 1088 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 11Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China, 12Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, 13JIANGMEN CENTRAL HOSPITAL, AFFILIATED JIANGMEN HOSPITAL OF SUN YAT-SEN UNIVERSITY, Jiangmen, China, 14The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, 15The First Affiliated Hospital of Harbin Medical University, Harbin, China, 16The Second Affiliated Hospital of Harbin Medical University, Harbin, China, 17The third hospital of hebei medical university, Shijiazhuang, China, 18Peace Hospital, Shijiazhuang, China, 19Henan Province Hospital of TCM, Zhengzhou, China, 20Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China

    Background/Purpose: Combination therapy with DMARDs for treating RA is considered as standard of care. However, certain rates of adverse events (AEs) are unavoidable. The stigma…
  • Abstract Number: 1536 • 2017 ACR/ARHP Annual Meeting

    Patient Preferences in Medication for Treatment of Spondyloarthritis: A Qualitative Study

    Maureen Dubreuil1, Christian Frese2, Shing Law3, Liana Fraenkel4, Elena Losina5 and Tuhina Neogi6, 1Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Rheumatology, Boston Medical Center, Boston, MA, 4Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, 5Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, 6Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Medications used in the treatment of spondyloarthritis (SpA) include nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics, with each class having distinct characteristics that patients may…
  • Abstract Number: 2194 • 2017 ACR/ARHP Annual Meeting

    The Relationship between the Number of Prescription Medications and Physical Activity Amongst Patients with or at High Risk for Knee Osteoarthritis

    Nivaas Thanoo1, Abigail Gilbert2, Jing Song3, Dorothy D. Dunlop4 and Rowland W. Chang5, 1Feinberg School of Medicine, Chicago, IL, 2Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Center for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Inst Hlthcare Studies, Northwestern Univ/ Feinberg, Chicago, IL, 5Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Physical activity amongst individuals with knee osteoarthritis (KOA) has been linked to improved pain, functional status, and less disability. It is important to understand…
  • Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting

    Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments

    Teresa Aberle1, Rufei Lu2, Sarah Cioli3, Stan Kamp1, Wade DeJager1, Stephen Apel4, Cristina Arriens5, Eliza Chakravarty6, Aikaterini Thanou1, Joel M. Guthridge7, Joan T. Merrill8 and Judith A. James9, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Oklahoma Medical research af, Edmond, OK, 7Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
  • Abstract Number: 52 • 2017 Pediatric Rheumatology Symposium

    How Young People with Juvenile Idiopathic Arthritis and Their Caregivers Weigh the Risks of the Disease and its Treatment: A Mixed-Methods Study

    Daniel B. Horton1,2, Jomaira Salas3, Aleksandra Wec4, Timothy Beukelman5,6, Alexis Boneparth1, Ky Haverkamp7, Melanie Kohlheim8, Melissa Mannion5, Nandini Moorthy1, Sarah Ringold9 and Marsha Rosenthal2, 1Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 3Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, 4Rutgers, the State University of New Jersey, New Brunswick, NJ, 5Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 7Family Medicine, University of Washington School of Medicine, Seattle, WA, 8Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, 9Seattle Children's Hospital, Seattle, WA

    Background/Purpose: Prior research has examined factors important to clinicians in deciding whether to withdraw therapy for inactive JIA, but little is known about the perspectives…
  • Abstract Number: 23 • 2017 Pediatric Rheumatology Symposium

    Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies

    Kelly Wise1, Dustin Lewis2, Bethanne Thomas2, Karla Jones3, Stephanie Lemle2, Darby MacDonald2, Fatima Barbar-Smiley2, Vidya Sivaraman2 and Cagri Yildirim-Toruner3, 1Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Rheumatology, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose:  Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes.  Biologics,…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology